Thromb Haemost 2003; 90(06): 1187-1191
DOI: 10.1160/TH03-05-0308
Vascular Development and Vessel Remodelling
Schattauer GmbH

Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis

Herbert K. Lau*
2   The Division of Hematology and Oncology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
,
Amit Segev*
1   The Roy and Ann Foss Cardiovascular Research Program, Terrence Donnelly Heart Center, Toronto, Ontario, Canada
,
Robert A. Hegele
3   The John P. Robarts Research Institute, London, Ontario, Canada
,
John D. Sparkes
1   The Roy and Ann Foss Cardiovascular Research Program, Terrence Donnelly Heart Center, Toronto, Ontario, Canada
,
Jerome M.Teitel
2   The Division of Hematology and Oncology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
,
Robert J. Chisholm
1   The Roy and Ann Foss Cardiovascular Research Program, Terrence Donnelly Heart Center, Toronto, Ontario, Canada
,
Bradley H. Strauss
1   The Roy and Ann Foss Cardiovascular Research Program, Terrence Donnelly Heart Center, Toronto, Ontario, Canada
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 21. Mai 2003

Accepted after resubmission 07. September 2003

Publikationsdatum:
05. Dezember 2017 (online)

Zoom Image

Summary

The fibrinolytic system is closely related to several processes that are involved in restenosis. We previously showed that low PAI-1 plasma levels predicted restenosis. Recently, a different fibrinolytic inhibitor, TAFI, has been described. The aims of this study were to evaluate the relationship between pre-procedural plasma levels of TAFI and late angiographic restenosis and the interaction between TAFI and PAI-1. We prospectively studied 159 patients with stable angina who underwent successful elective angioplasty or stenting of de novo native coronary artery lesions. TAFI and PAI-1 antigen levels were measured in plasma samples drawn before the procedure. Follow-up coronary angiography was performed in 92% of patients. There was a significant correlation between pre-procedural TAFI levels and 6-month % diameter stenosis (DS) (r = 0.21; p = 0.013). The overall angiographic restenosis rate (DS>50%) was 31%. Pre-procedural TAFI levels were significantly higher in patients with restenosis (108 ± 33% versus 94±30%, p = 0.011). Restenosis rates for patients in the upper tertile of TAFI levels were 2-fold higher than for those in the lowest tertile (45% versus 22%; p = 0.016). A combination of high TAFI and low PAI-1 levels identified patients at the highest risk of restenosis (53%) compared to 14% in patients with low TAFI and high PAI-1 levels; p = 0.027. In conclusion, pre-procedural plasma TAFI antigen levels identify patients at increased risk for restenosis after PCI.

* Both authors contributed equally to this work